EDX Medical Group has entered a partnership with Caris Life Sciences to distribute the latter's molecular profiling services in the UK and Nordic countries. Financial terms and other details of the agreement were undisclosed.

The partnership will be focused on providing Caris' advanced molecular profiling services for both clinical and research uses for a minimum of three years. This service leverages DNA, RNA, and protein examination to create a unique molecular blueprint for each patient's cancer, guiding individualized treatment decisions. The partnership aims to make these services immediately accessible in the UK, Sweden, Denmark, Norway, and Finland, with future expansion planned in other regions.

UK-based EDX Medical Group is a digital diagnostics company focused on developing and delivering testing solutions. Its primary offerings include digital diagnostic products and services targeting cancer, cardiovascular disease, neurology, and infectious diseases. The company's approach combines advanced biological and digital technologies to improve disease risk detection and personalize disease management efficiently​.

Analyst QuickTake: In June 2024, Caris Life Sciences entered a commercial distribution agreement with Juniper Biologics for its tumor profiling services in the Middle East and Africa (MEA) regions. This expansion followed Juniper’s partnership with Caris to expand the same services to Southeast Asia (SEA) regions.